L H Lindholm

Summary

Country: Sweden

Publications

  1. ncbi request reprint Major benefits from cholesterol-lowering in patients with diabetes
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, SE 901 85, Umea, Sweden
    Lancet 361:2000-1. 2003
  2. ncbi request reprint Prevention of cardiovascular disease in developing countries
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, SE 901 85 Umea, Sweden
    Lancet 370:720-2. 2007
  3. ncbi request reprint Beta blockers in primary hypertension: Do age and type of beta-blocker matter?
    Lars Hjalmar Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, Umea, Sweden
    J Hypertens 24:2143-5. 2006
  4. ncbi request reprint Cost implications of development of diabetes in the ALPINE study
    Lars H Lindholm
    Umea University Hospital, Umea, Gothenburg, Sweden
    J Hypertens Suppl 24:S65-72. 2006
  5. ncbi request reprint Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis
    Lars Hjalmar Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, Umea, Sweden
    Lancet 366:1545-53. 2005
  6. ncbi request reprint Valsartan treatment of hypertension--does VALUE add value?
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, SE 901 85 Umea, Sweden
    Lancet 363:2010-1. 2004
  7. ncbi request reprint Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, SE 901 85, Umea, Sweden
    Lancet 362:619-20. 2003
  8. ncbi request reprint What are the odds at ASCOT today?
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, SE 901 85, Umea, Sweden
    Lancet 361:1144-5. 2003
  9. ncbi request reprint Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
    Lars H Lindholm
    Steno Diabetes Centre, Gentofte, Denmark
    J Hypertens 20:1879-86. 2002
  10. ncbi request reprint Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial
    L H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, SE 901 85, Umea, Sweden
    Lancet 358:539-44. 2001

Detail Information

Publications22

  1. ncbi request reprint Major benefits from cholesterol-lowering in patients with diabetes
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, SE 901 85, Umea, Sweden
    Lancet 361:2000-1. 2003
  2. ncbi request reprint Prevention of cardiovascular disease in developing countries
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, SE 901 85 Umea, Sweden
    Lancet 370:720-2. 2007
  3. ncbi request reprint Beta blockers in primary hypertension: Do age and type of beta-blocker matter?
    Lars Hjalmar Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, Umea, Sweden
    J Hypertens 24:2143-5. 2006
  4. ncbi request reprint Cost implications of development of diabetes in the ALPINE study
    Lars H Lindholm
    Umea University Hospital, Umea, Gothenburg, Sweden
    J Hypertens Suppl 24:S65-72. 2006
    ..To present a cost-effectiveness analysis of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation study (ALPINE)...
  5. ncbi request reprint Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis
    Lars Hjalmar Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, Umea, Sweden
    Lancet 366:1545-53. 2005
    ..However, a preliminary analysis has shown that atenolol is not very effective in hypertension. We aim to substantially enlarge the data on atenolol and analyse the effect of different beta blockers...
  6. ncbi request reprint Valsartan treatment of hypertension--does VALUE add value?
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, SE 901 85 Umea, Sweden
    Lancet 363:2010-1. 2004
  7. ncbi request reprint Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, SE 901 85, Umea, Sweden
    Lancet 362:619-20. 2003
    ..Our results suggest losartan affords better protection against cardiac death from arrhythmias for patients with diabetes mellitus than does atenolol. Importantly, our analyses were exploratory and require confirmation...
  8. ncbi request reprint What are the odds at ASCOT today?
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, SE 901 85, Umea, Sweden
    Lancet 361:1144-5. 2003
  9. ncbi request reprint Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
    Lars H Lindholm
    Steno Diabetes Centre, Gentofte, Denmark
    J Hypertens 20:1879-86. 2002
    ..There has been uncertainty about the risk of new-onset diabetes in hypertensive individuals treated with different blood pressure-decreasing drugs...
  10. ncbi request reprint Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial
    L H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, SE 901 85, Umea, Sweden
    Lancet 358:539-44. 2001
    ..We have also looked at the frequency of cancer in these patients...
  11. ncbi request reprint The problem of uncontrolled hypertension
    L H Lindholm
    Department of Public Health and Clinical Medicine, Norrlands University Hospital, Umea, Sweden
    J Hum Hypertens 16:S3-8. 2002
    ..AT(1)-receptor blockers could thus make a potentially important contribution to solving the problem of uncontrolled hypertension...
  12. ncbi request reprint Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
    Lars H Lindholm
    Umea University Hospital, Sweden
    Lancet 359:1004-10. 2002
    ..In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients...
  13. ncbi request reprint The status of hypertension therapy
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, Sweden
    J Hypertens Suppl 20:S1. 2002
  14. ncbi request reprint High remaining risk in poorly treated hypertension: the 'rule of halves' still exists
    Lars Weinehall
    Epidemiology, Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden
    J Hypertens 20:2081-8. 2002
    ....
  15. ncbi request reprint Evaluation of a computer-based decision support system for treatment of hypertension with drugs: retrospective, nonintervention testing of cost and guideline adherence
    M Persson
    Department of Public Health, University of Umea, Department of Pharmacology, Sweden
    J Intern Med 247:87-93. 2000
    ..To evaluate a computerized decision support system (DSS) for drug treatment of hypertension, regarding quality, safety, and cost compared to actual antihypertensive drug treatment...
  16. ncbi request reprint Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy
    Mats Persson
    Department of Public Health and Clinical Medicine, University of Umea, Sweden
    J Hypertens 22:65-71. 2004
    ..We studied the differences between recommendations given in the 1999 World Health Organization-International Society of Hypertension (WHO/ISH) Guidelines and doctors' risk estimation and willingness to give antihypertensive drugs...
  17. ncbi request reprint Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)
    Lars H Lindholm
    Umea University Hospital, Umea, Sweden
    J Hypertens 21:1563-74. 2003
    ..The objectives included comparisons of the effects on the glucose metabolism, lipoprotein metabolism, electrolytes, blood pressure, and subjective symptoms...
  18. ncbi request reprint Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample
    Mats Persson
    aDepartment of Public Health and Clinical Medicine and bDepartment of Mathematical Statistics, University of Umea, Sweden
    J Hypertens 21:1089-95. 2003
    ..Risk equations estimated by statistical methods are another way of predicting cardiovascular risk...
  19. ncbi request reprint Accuracy of a first diagnosis of asthma in primary health care
    Peter Montnemery
    Department of Clinical Neuroscience Division of Occupational Therapy, PO Box 157, Umea University, SE 221 00 Lund, Sweden
    Fam Pract 19:365-8. 2002
    ..5%. However, the register prevalence of asthma obtained from the medical records in the same municipality and age groups was found to be only 2.1%...
  20. ncbi request reprint A goose named Lindholm
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden
    Lancet 359:1720. 2002
  21. ncbi request reprint Atenolol in hypertension: is it a wise choice?
    Bo Carlberg
    Department of Public Health and Clinical Medicine, Umea University Hospital, SE 901 85 Umea, Sweden
    Lancet 364:1684-9. 2004
    ..Thus, our aim was to systematically review the effect of atenolol on cardiovascular morbidity and mortality in hypertensive patients...
  22. ncbi request reprint [Reply from the SBU about salt and high blood pressure: More controlled long-term trials are required]
    Mats Halldin
    Lakartidningen 101:4257. 2004